Back to search

BIA-Brukerstyrt innovasjonsarena

Innovation on Signalling Disruptors - Development of drugs eliminating cAMP action in infectious disease (HIV/AIDS) and cancer

Awarded: NOK 6.0 mill.

Project Number:

179867

Project Period:

2007 - 2009

Funding received from:

Organisation:

Subject Fields:

Partner countries:

Compartmentalised cAMP-dependent signalling is involved in development of a number of diseases including HIV/AIDS, certain types of cancer, and other types of immunodeficiencies which affect several million citizens both in industrialised and developing c ountries each year. No organised approach has specifically aimed at targeted disruption of cAMP signalling pathways in such diseases. Most of the diseases described above cannot be properly cured by available therapies. This is particularly the case for i mmunodeficiencies and the failure of the immune system in certain cases of cancer. Work in this project will involve development of isozyme-specific cAMP antagonists which are already synthesised and patented, and can be produced in sufficient quantities for proof-of-concept in cells and animals, and subsequently put in preclinical and clinical testing. The research team and commercial unit bring together various complementary competences across the cell signalling field to develop drugs for treatment of important diseases and have expertise on drug design, synthesis and delivery. We have cell-based and animal disease models for the group of diseases.

Funding scheme:

BIA-Brukerstyrt innovasjonsarena